The "Cerebrospinal Fluid Sink Therapeutic Strategy" in Alzheimer's Disease-From Theory to Design of Applied Systems

被引:9
|
作者
Schreiner, Thomas Gabriel [1 ,2 ,3 ]
Menendez-Gonzalez, Manuel [4 ,5 ,6 ]
Popescu, Bogdan Ovidiu [1 ,7 ,8 ]
机构
[1] Univ Med & Pharm Carol Davila, Fac Med, Bucharest 050474, Romania
[2] Univ Med & Pharm Gr T Popa, Dept Neurol, Iasi 700115, Romania
[3] Gheorghe Asachi Tech Univ Iasi, Fac Elect Engn & Informat Technol, Dept Elect Measurements & Mat, Iasi 700050, Romania
[4] Univ Oviedo, Dept Med, Oviedo 33006, Spain
[5] Hosp Univ Cent Asturias, Dept Neurol, Oviedo 33006, Spain
[6] Inst Invest Sanitaria Principado Asturias, Oviedo 33006, Spain
[7] Colentina Clin Hosp, Neurol Dept, Bucharest 020125, Romania
[8] Victor Babes Natl Inst Pathol, Lab Cell Biol Neurosci & Expt Myol, Bucharest 050096, Romania
关键词
Alzheimer's disease; amyloid-beta; cerebrospinal fluid; therapy; implantable device; clearance; AMYLOID-BETA; MOUSE MODEL; NEPRILYSIN; CLEARANCE;
D O I
10.3390/biomedicines10071509
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Alzheimer's disease (AD) is a global health problem, with incidence and prevalence considered to increase during the next decades. However, no currently available effective treatment exists despite numerous clinical trials in progress. Moreover, although many hypotheses are accepted regarding the pathophysiological mechanisms of AD onset and evolution, there are still many unknowns about the disorder. A relatively new approach, based on the amyloid-beta dynamics among different biological compartments, is currently intensely discussed, as it seems to offer a promising solution with significant therapeutic impact. Known as the "cerebrospinal-fluid-sink therapeutic strategy", part of the "three-sink therapeutic strategy", this theoretical model focuses on the dynamics of amyloid-beta among the three main liquid compartments of the human body, namely blood, cerebrospinal fluid, and the (brain) interstitial fluid. In this context, this article aims to describe in detail the abovementioned hypothesis, by reviewing in the first part the most relevant anatomical and physiological aspects of amyloid-beta dynamics. Subsequently, explored therapeutic strategies based on the clearance of amyloid-beta from the cerebrospinal fluid level are presented, additionally highlighting their limitations. Finally, the originality and novelty of this work rely on the research experience of the authors, who focus on implantable devices and their utility in AD treatment.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Tau oligomers in cerebrospinal fluid in Alzheimer's disease
    Sengupta, Urmi
    Portelius, Erik
    Hansson, Oskar
    Farmer, Kathleen
    Castillo-Carranza, Diana
    Woltjer, Randall
    Zetterberg, Henrik
    Galasko, Douglas
    Blennow, Kaj
    Kayed, Rakez
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2017, 4 (04): : 226 - 235
  • [32] A cerebrospinal fluid biosignature for the diagnosis of Alzheimer's disease
    Barichello, Tatiana
    Giridharan, Vijayasree V.
    Dal-Pizzol, Felipe
    BRAZILIAN JOURNAL OF PSYCHIATRY, 2019, 41 (06) : 467 - 468
  • [33] Cerebrospinal fluid biomarkers in Alzheimer's disease Discussion
    Komajda, Michel
    Netter, Patrick
    Villet, Richard
    Dreux, Claude
    Giudicelli, Claude-Pierre
    Grosgogeat, Yves
    Junien, Claudine
    Chouard, Claude-Henri
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2018, 202 (1-2): : 318 - 320
  • [34] Cerebrospinal Fluid Protein Biomarkers for Alzheimer's Disease
    Blennow K.
    NeuroRX, 2004, 1 (2): : 213 - 225
  • [35] Targeted Recruitment Using Cerebrospinal Fluid Biomarkers: Implications for Alzheimer's Disease Therapeutic Trials
    Barnes, Josephine
    Bartlett, Jonathan W.
    Fox, Nick C.
    Schott, Jonathan M.
    JOURNAL OF ALZHEIMERS DISEASE, 2013, 34 (02) : 431 - 437
  • [36] Clearing Extracellular Alpha-Synuclein from Cerebrospinal Fluid: A New Therapeutic Strategy in Parkinson's Disease
    Menendez-Gonzalez, Manuel
    Padilla-Zambrano, Huber S.
    Tomas-Zapico, Cristina
    Fernandez Garcia, Benjamin
    BRAIN SCIENCES, 2018, 8 (04):
  • [37] Current therapeutic strategy in Alzheimer's disease
    Singh, S.
    Kushwah, A. S.
    Singh, R.
    Farswan, M.
    Kaur, R.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2012, 16 (12) : 1651 - 1664
  • [38] Appropriateness of Applying Cerebrospinal Fluid Biomarker Cutoffs from Alzheimer's Disease to Parkinson's Disease
    Weinshel, Sarah
    Irwin, David J.
    Zhang, Panpan
    Weintraub, Daniel
    Shaw, Leslie M.
    Siderowf, Andrew
    Xie, Sharon X.
    JOURNAL OF PARKINSONS DISEASE, 2022, 12 (04) : 1155 - 1167
  • [39] β-amyloid (Aβ) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease
    Andreasen, N
    Blennow, K
    PEPTIDES, 2002, 23 (07) : 1205 - 1214
  • [40] Klotho in the cerebrospinal fluid of adults with and without Alzheimer's disease
    Semba, Richard D.
    Moghekar, Abhay R.
    Hu, Jason
    Sun, Kai
    Turner, Randi
    Ferrucci, Luigi
    O'Brien, Richard
    NEUROSCIENCE LETTERS, 2014, 558 : 37 - 40